The CNS specialists are planning an expansion into Poland, jump starting the process with the creation of Neuraxpharm Polska
Until now, Neuraxpharm has provided its medicines to CNS specialists and patients in Poland through its German subsidiary. Now the pharmaceutical company is launching Neuraxpharm Polska to expand its presence in the country.
Dr Wojciech Góra has been appointed to General Manager to spearhead the business. Gora brings over 20 years of experience in building and managing European pharmaceuticals operations and will be responsible for Neuraxpharm Polska located in Warsaw.
A key pillar of Neuraxpharm’s growth strategy is to establish its own operations in high growth markets in Europe. Neuraxpharm aims to build its position as a CNS specialist in Poland offering nutraceuticals, standard generics and added value medicines and plans to launch five new CNS products in 2019.
Neuraxpharm is investing in its pipeline by developing differentiated and high-tech barrier products in CNS that will be launched in Poland as well as in other Neuraxpharm countries.
Commenting on the news, Dr Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “Neuraxpharm today has a direct presence in nine European countries and establishing Neuraxpharm Polska reinforces our ambition to be a leading CNS player in the CEE region and help bring differentiated products to local patients and healthcare professionals.”
Dr Wojciech Góra, newly appointed General Manager, Neuraxpharm Polska added: “Poland is the sixth biggest CNS European market with double-digit growth. I look forward to building and establishing Neuraxpharm as a recognised and trusted partner as we look towards launching new CNS products in the region.”